This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Dr David Clarke Ph.D

Dr David Clarke Ph.D


Dr David Clarke Ph.D FBPhS


Afferent Pharmaceuticals (CA) and Recordati (Italy)

Year elected:


Primary professional setting:


Professional Status: 1969-present: Preclinical Consultant for Afferent Pharmaceuticals, CA, USA (now Merck) and Recordati, Milan, Italy. Distinguished Scientist at Syntex/Roche, CA, USA 1989-1996: Professor of Pharmacology, University of Houston, TX, USA 1973-1989: University of Pittsburgh, 1969-1973: University of Bradford, 1961-1969.Discoveries: SSAO linked with diabetes (with Barbara Hayes): Discovery/definition of the 5HT-4 receptor (with Doug Craig): Discovery of the beta-3-adrenoceptor, identifying nadolol as first antagonist (with Richard Bond): Discovery/classification of the alpha-1A/1L-adrenoceptor (with Anthony Ford): First to equate the alpha-1A with alpha-1L receptor and the alpha-1D with the alpha-1C receptor; led to the deletion of the alpha-1C appellation. (All research above has contributed to the discovery of novel therapeutic agents.) Initiated a P2X3 antagonist programme at Roche and consulted with Anthony Ford (Programme Leader) through Afferent to present status (Phase 3) with Merck (MK-7264/AF-219: First drug in class).